ATE461713T1 - Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren - Google Patents

Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren

Info

Publication number
ATE461713T1
ATE461713T1 AT03730342T AT03730342T ATE461713T1 AT E461713 T1 ATE461713 T1 AT E461713T1 AT 03730342 T AT03730342 T AT 03730342T AT 03730342 T AT03730342 T AT 03730342T AT E461713 T1 ATE461713 T1 AT E461713T1
Authority
AT
Austria
Prior art keywords
radioimmunotherapy
compositions
radionuclide
brain tumors
carrier
Prior art date
Application number
AT03730342T
Other languages
English (en)
Inventor
Gary Griffiths
David Goldenberg
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE461713T1 publication Critical patent/ATE461713T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AT03730342T 2002-05-29 2003-05-28 Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren ATE461713T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38361702P 2002-05-29 2002-05-29
PCT/GB2003/002334 WO2003101495A1 (en) 2002-05-29 2003-05-28 Methods and compositions for radioimmunotherapy of brain and cns tumors

Publications (1)

Publication Number Publication Date
ATE461713T1 true ATE461713T1 (de) 2010-04-15

Family

ID=29711935

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03730342T ATE461713T1 (de) 2002-05-29 2003-05-28 Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren

Country Status (8)

Country Link
US (1) US20030235534A1 (de)
EP (1) EP1507562B1 (de)
JP (1) JP2005532343A (de)
AT (1) ATE461713T1 (de)
AU (1) AU2003241024A1 (de)
CA (1) CA2487692A1 (de)
DE (1) DE60331827D1 (de)
WO (1) WO2003101495A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7521531B2 (en) * 1996-08-28 2009-04-21 Immunomedics, Inc. Methods for the purification of stable radioiodine conjugates
US7405320B2 (en) 1998-06-22 2008-07-29 Immunomedics, Inc. Therapeutic and diagnostic conjugates for use with multispecific antibodies
US7172751B2 (en) * 2003-06-13 2007-02-06 Immunomedics, Inc. D-amino acid peptides
US20100068151A1 (en) * 2008-03-11 2010-03-18 Rosenblum Michael G Multimodality molecular imaging with therapeutic conjugates
JP6092624B2 (ja) 2009-06-12 2017-03-08 セレクター，インコーポレイティド 癌の治療並びに癌幹細胞の造影および検出のためのエーテルおよびアルキルリン脂質化合物
LT2535358T (lt) * 2010-02-10 2018-03-26 Fujifilm Ri Pharma Co., Ltd. Radioaktyvus metalu žymėtas anti-kadherino antikūnas
RU2664698C2 (ru) 2011-12-13 2018-08-21 Энджинеик Молекьюлар Деливери Пти Лтд Полученные из бактерий интактные мини-клетки для доставки лекарственных средств к опухолям мозга
ES3058443T3 (es) 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
DK3470418T3 (da) * 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
CA3108044A1 (en) * 2018-07-31 2020-02-06 Daiichi Sankyo Company, Limited Treatment of metastatic brain tumor by administration of antibody-drug conjugate
AU2021342126A1 (en) * 2020-09-10 2023-05-18 City Of Hope Combination therapy comprising cancer-targeted car-t cells and a method of using same for a treatment for cancer
WO2022167052A1 (en) 2021-02-08 2022-08-11 Y-Mabs Therapeutics, Inc. Use of ascorbic acid as stabilizing agent for anti b7-h3 antibodies

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4348376A (en) * 1980-03-03 1982-09-07 Goldenberg Milton David Tumor localization and therapy with labeled anti-CEA antibody
US4818706A (en) * 1983-04-19 1989-04-04 American Monitor Corporation Reagent-dispensing system and method
US4732864A (en) * 1983-10-06 1988-03-22 E. I. Du Pont De Nemours And Company Trace-labeled conjugates of metallothionein and target-seeking biologically active molecules
US4824659A (en) * 1985-06-07 1989-04-25 Immunomedics, Inc. Antibody conjugates
FR2604092B1 (fr) * 1986-09-19 1990-04-13 Immunotech Sa Immunoreactifs destines a cibler les cellules animales pour leur visualisation ou leur destruction in vivo
US5019368A (en) * 1989-02-23 1991-05-28 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US4900684A (en) * 1987-06-01 1990-02-13 Immunomedics, Inc. CEA immunoassay free of human anti-mouse antibody false positives
US5612016A (en) * 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5460785A (en) * 1989-08-09 1995-10-24 Rhomed Incorporated Direct labeling of antibodies and other protein with metal ions
US5965132A (en) * 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
PT627940E (pt) * 1992-03-05 2003-07-31 Univ Texas Utilizacao de imunoconjugados para o diagnostico e/ou terapia de tumores vascularizados
DE69332952T2 (de) * 1992-09-04 2004-02-19 The General Hospital Corp., Boston Diagnostische und therapeutische Einheiten enthaltende biokompatible Polymere
US5998222A (en) * 1993-11-29 1999-12-07 Utah State University Reconditioning antibiotic-adulterated milk products
AU2194695A (en) * 1994-03-28 1995-10-17 Regents Of The University Of California, The Method for preparing radionuclide-labeled chelating agent-ligand complexes
US5874540A (en) * 1994-10-05 1999-02-23 Immunomedics, Inc. CDR-grafted type III anti-CEA humanized mouse monoclonal antibodies
EP0975374B1 (de) * 1996-07-12 2007-12-05 Immunomedics, Inc. Radiometall-bindende peptide analoge
US6306393B1 (en) * 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US6183744B1 (en) * 1997-03-24 2001-02-06 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
US7074405B1 (en) * 1998-06-22 2006-07-11 Immunomedics, Inc. Use of bi-specific antibodies for pre-targeting diagnosis and therapy
US6342219B1 (en) * 1999-04-28 2002-01-29 Board Of Regents, The University Of Texas System Antibody compositions for selectively inhibiting VEGF
US7011816B2 (en) * 2001-12-26 2006-03-14 Immunomedics, Inc. Labeling targeting agents with gallium-68 and gallium-67

Also Published As

Publication number Publication date
DE60331827D1 (de) 2010-05-06
JP2005532343A (ja) 2005-10-27
CA2487692A1 (en) 2003-12-11
US20030235534A1 (en) 2003-12-25
EP1507562A1 (de) 2005-02-23
AU2003241024A1 (en) 2003-12-19
EP1507562B1 (de) 2010-03-24
WO2003101495A1 (en) 2003-12-11

Similar Documents

Publication Publication Date Title
RU2342159C2 (ru) Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
WO2002083171A3 (en) Cancer treatment by using fap-alpha specific antibodies
MXPA03010121A (es) Terapia de combinacion que utiliza anticuerpos anti-receptor de factor de crecimiento epidermico y agentes anti-hormonales.
CY1112473T1 (el) Μεθοδοι θεραπειας για καρκινους σχετιζομενους με β κυτταρα
NO2017019I1 (no) Diarylhydantoinforbindelse, farmasøytisk sammensetning og anvendelse derav
RU2008150250A (ru) Способ лечения рака
UA94899C2 (ru) Фиксированное дозирование антител к her
EA200800268A1 (ru) КОМБИНИРОВАННАЯ ТЕРАПИЯ АНТИТЕЛОМ ПРОТИВ CTLA-4 И СОДЕРЖАЩИМ CpG-МОТИВ СИНТЕТИЧЕСКИМ ОЛИГОДЕЗОКСИНУКЛЕОТИДОМ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННОЙ ОПУХОЛИ
EP2509627A4 (de) Verfahren für eine verstärkte tumorantikörpertherapie
CY1113287T1 (el) Μεθοδοι αγωγης του καρκινου χρησιμοποιωντας il-21 και θεραπεια με μονοκλωνικα αντισωματα
CY1109607T1 (el) Παραγωγο εποθιλονης για τη θεραπευτικη αντιμετωπιση του ηπατωματος και αλλων κακοηθων νοσων
BR0306715A (pt) Métodos para diagnóstico e tratamento de tumores
DK1565471T3 (da) Quionolinylpyrazoler
ATE461713T1 (de) Zusammensetzungen für die radioimmuntherapie von gehirn-tumoren
IS6558A (is) Blandaðar sjúkdómsmeðferðir með æðaskaðandi virkni
EA200700686A1 (ru) Липосомы, включающие радиоактивный изотоп, и цитотоксический агент для комбинированной терапии
AU2003244762A1 (en) Methods and compositions for intravesical therapy of bladder cancer
DK1684770T3 (da) Oligo-beta-(1, 3) -glucan og monoklonale antistoffer mod kræft
MX2024014265A (es) Complejos radiofarmaceuticos dirigidos al antigeno prostatico especifico de membrana y sus combinaciones
BR0309226A (pt) Métodos para a produção de um efeito de danificação vascular em um animal de sangue quente, e para o tratamento de um câncer envolvendo um tumor sólido em um animal de sangue quente, composição farmacêutica, kit, e, usos de zd6126 ou de um seu sal farmaceuticamente aceitável, e de zd1839 ou de um seu sal farmaceuticamente aceitável
BRPI0512040A (pt) composição farmacêutica, método de modificação de receptores de célula de tumor, método de aperfeiçoar seletividade alvo de anticorpos, método de tratar cáncer, kit, uso de prolina
EA200300646A1 (ru) Иммунотерапевтический набор для лечения опухолей
BR0215689A (pt) Composição farmacêutica compreendendo arsênico para o tratamento de malignidade
TW200608959A (en) Treatment with oxaliplatin and an egfr-inhibitor
EA200600987A1 (ru) Применение сирамезина в лечении злокачественных опухолей

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties